KRAS protein is a GTPase and plays a crucial role in downstream signaling pathways. The activity of KRAS protein is regulated by the ratio of GTP to GDP bound to it. When GTP is bound to KRAS protein, it activates downstream signaling pathways, promoting cell proliferation and survival. However, mutations in the KRAS gene, such as GQ60GK, can lead to the activation of KRAS protein, resulting in the constant activation of downstream signaling pathways and promoting cancer cell proliferation and metastasis. when KRAS undergoes the Q61K mutation, it becomes constitutively activated, even in the absence of activation by EGFR or other kinases, leading to continuous cell proliferation and ultimately cancer development. The KRAS (mutated Q61K) mutation is found in various types of tumors, most notably lung cancer and pancreatic cancer. In clinical treatment, the presence of this mutation may require the adoption of specific therapeutic strategies, as some targeted drugs designed for non-mutated KRAS may be ineffective against this mutant form.